S&P 500
3,339.19-9.97(-0.30%)Nasdaq
11,076.45-31.62(-0.28%)Russell 2000
1,544.62-1.61(-0.10%)
Poseida Therapeutics, Inc. (PSTX)
Chart Events
Performance Outlook
| Previous Close | 12.68 |
| Open | 12.56 |
| Bid | 12.75 x 1200 |
| Ask | 13.19 x 800 |
| Day's Range | 12.56 - 13.18 |
| 52 Week Range | 11.35 - 17.62 |
| Volume | 8,162 |
| Avg. Volume | 927,505 |
| Market Cap | 785.68M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.22 |
- PR Newswire
Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced biotech veteran Harry J. Leonhardt, Esq. has joined the company as General Counsel and Chief Compliance Officer.
- MarketWatch
Poseida Therapeutics' stock opens higher, then seesaws around the IPO price
Shares of Poseida Therapeutics Inc. kicked off their public life with a gain, after the biopharmaceutical company's initial public offering priced at the top of the expected range, but those gains quickly faded. The stock's first trade was at $17, or 6.3% above the $16 IPO price, at 11:09 a.m. Eastern for 1.1 million shares. The stock first traded below its IPO price at 11:12 a.m., and fell to an intraday low of $15.20, so far, before bouncing back above its IPO price. The company raised $204.8 million in the IPO after expenses. The stock has gone public at a time that the Renaissance IPO ETF run up 62.3% over the past three months, to outperform the S&P 500's 13.3% gain over the same period.
